2004
DOI: 10.1007/s00280-004-0909-8 View full text |Buy / Rent full text
|
|

Abstract: The regimen consisting of docetaxel 30 mg/m2 (days 1, 8) and capecitabine 825 mg/m2 twice daily (days 1-14) was well tolerated. Capecitabine did not alter pharmacokinetics of docetaxel. Further testing of this regimen in tumor-specific trials, especially gastric, lung and breast cancer, is warranted.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
0
9
0

Year Published

2006
2006
2013
2013

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

0
9
0
Order By: Relevance
“…Given preclinical evidence of synergy and data from our phase I study, and in an effort to potentially simplify treatment and reduce toxicity, a multi-institutional phase II study combining docetaxel (Sanofi-Aventis, Bridgewater, N.J., USA) and capecitabine (Hoffman La-Roche, Nutley, N.J., USA), 2 agents with single-agent activity in gastric and GE junction adenocarcinomas [4,5,6,7,8,9,10,11,12,13], was performed.…”
Section: Introductionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Given preclinical evidence of synergy and data from our phase I study, and in an effort to potentially simplify treatment and reduce toxicity, a multi-institutional phase II study combining docetaxel (Sanofi-Aventis, Bridgewater, N.J., USA) and capecitabine (Hoffman La-Roche, Nutley, N.J., USA), 2 agents with single-agent activity in gastric and GE junction adenocarcinomas [4,5,6,7,8,9,10,11,12,13], was performed.…”
Section: Introductionmentioning
“…This has led us to replace 5 fluorouracil with capecitabine, which is administered orally and is better accepted by patients, its main side effects being hand and foot syndrome and diarrhea. Capecitabine combination doses between 825 and 1,050 mg/m 2 twice daily are recommendable [11,12]. With regard to SCCHN, capecitabine at a dose of 1,000 mg/m 2 twice daily has been associated with both cisplatin and docetaxel, and encouraging activity and safety data were observed [13,14].…”
Section: Discussionmentioning
“…Several interactions have already been discussed by Baker et al. [38]: there is no interaction between docetaxel and 5‐FU [38,65,66], carboplatin [38,67,68], epirubicin [38,69,70], vinorelbine [38,71], gemcitabine [38,72], methotrexate [38,73], capecitabine [38,74,75], ifosfamide [38,76], estramustine [38,77] or irinotecan [38,78,79]. Baker et al.…”
Section: Sources Of Variabilitymentioning
“…It is therefore obvious that all new combination drug regimens with docetaxel are subject of PK studies. Several interactions have already been discussed by Baker et al [38]: there is no interaction between docetaxel and 5-FU [38,65,66], carboplatin [38,67,68], epirubicin [38,69,70], vinorelbine [38,71], gemcitabine [38,72], methotrexate [38,73], capecitabine [38,74,75], ifosfamide [38,76], estramustine [38,77] or irinotecan [38,78,79]. Baker et al [38] also report that the combination of doxorubicin and docetaxel results in a decreased clearance of the latter product, but the importance of the order of administration seems less obvious than for paclitaxel.…”
Section: Drug-drug Interactionsmentioning